Skip to main content
Clinical Trials/NCT05707429
NCT05707429CompletedNot Applicable

Sexual Function and Quality of Life Among Patients Suffering From Inflammatory Bowel Disease During Remmsion

Assiut University1 site in 1 country80 target enrollmentStarted: February 1, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
80
Locations
1
Primary Endpoint
inactive IBD &sexual function of both males

Study Overview

Brief Summary

Sexual dysfunction [SD] is a significant health burden characterized by a disturbance in sexual desire and psychophysiological changes in the sexual response cycle, resulting in marked distress and interpersonal difficulty (4). As known, both SD and depression are interrelated, so, depression may be an important determinant of sexual functioning in patients with IBD(5).

Detailed Description

Inflammatory Bowel Diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are characterized by a chronically relapsing course (1).

IBD is likely to have a substantial impact on body image, intimacy and sexuality, Because of symptoms like abdominal pain, fatigue, bloating, gas, and diarrhea (2).

Complications may include perianal disease, fistulae and abscesses. Surgery is frequently necessary, sometimes including the placement of a stoma or pouch. Furthermore, mood disorders, mainly depression, are reported to be common in IBD (3) .

Sexual dysfunction [SD] is a significant health burden characterized by a disturbance in sexual desire and psychophysiological changes in the sexual response cycle, resulting in marked distress and interpersonal difficulty (4). As known, both SD and depression are interrelated, so, depression may be an important determinant of sexual functioning in patients with IBD(5).

For female IBD patients, SD mainly manifests as decreased sexual desire, orgasm, and sexual arousal disorder, while for men, the most common symptom is erectile dysfunction (ED) (6).

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • 18-50 years old.
  • Both sexes
  • A stable sexual partner for ≥3 months
  • ability to fill in and understand the questionnaire
  • sign informed consent and participate voluntarily. For control group: An age-matched control group of healthy men and women, in the same region will also be invited to participate. The controls will eligible if they are 18-50 years of age, have a stable heterosexual relationship for at least 3 months and do not have bowel like IBD or irritable bowel syndrome or psychiatric problems.

Exclusion Criteria

  • Those who couldn't understand or fill out the questionnaire themselves and/or those with mental disorders
  • Diagnosis of SD before an IBD diagnosis
  • SD compounded by other diseases: cardiovascular and cerebrovascular diseases, lung diseases, liver and kidney dysfunction, diabetic neuropathy, other psychiatric disorders (e.g. depression), and neoplastic diseases, etc.
  • History or current use of psychotropic drugs or medications have sexual side effects.

Outcomes

Primary Outcomes

inactive IBD &sexual function of both males

Time Frame: 3 months

using questionnaire IIEF-5 score It consists of five questions, including vaginal penetration, maintenance of erection, completion of intercourse, sexual satisfaction, and self-confidence of the patient's sexual arousal and maintenance of an erection * A total score of \< 22 is defined as ED . females using FSFI score. * The optimal cutoff score of the FSFI is 26.55, which means that a score at or below this value is defined as female SD

Secondary Outcomes

  • Mean scores for quality of life among inactive IBD patients(3 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Bahaa osman taha

assistant lecturer

Assiut University

Study Sites (1)

Loading locations...

Similar Trials

Sexual Function and Quality of Life Among... | Clinical Trial